{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:08:59Z","timestamp":1785240539818,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jvacx.2019.100048","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:36:55Z","timestamp":1574199415000},"page":"100048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in L. infantum-infected dogs"],"prefix":"10.1016","volume":"4","author":[{"given":"Leopoldo F.M.","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayane Francisca Higino","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana D.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviane A.","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Loureiro","family":"Werneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-5516","authenticated-orcid":false,"given":"Malcolm S.","family":"Duthie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldina","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel","family":"Barral-Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.P.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2019.100048_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7705\/biomedica.v34i1.2153","article-title":"Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America","volume":"34","author":"Travi","year":"2014","journal-title":"Biomedica"},{"key":"10.1016\/j.jvacx.2019.100048_b0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-3164.2005.00460.x","article-title":"Treatment of canine Old World visceral leishmaniasis: a systematic review","volume":"16","author":"Noli","year":"2005","journal-title":"Vet Dermatol"},{"key":"10.1016\/j.jvacx.2019.100048_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/DDDT.S146521","article-title":"Leishmaniasis in humans: drug or vaccine therapy?","volume":"12","author":"Ghorbani","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jvacx.2019.100048_b0020","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.jvacx.2019.100048_b0025","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0030","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0035","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jvacx.2019.100048_b0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jvacx.2019.100048_b0050","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1038\/cti.2016.63","article-title":"A structure-function approach to optimizing TLR4 ligands for human vaccines","volume":"5","author":"Carter","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jvacx.2019.100048_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1590\/0074-02760160305","article-title":"Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil","volume":"112","author":"Silva","year":"2017","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.jvacx.2019.100048_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.rvsc.2008.12.009","article-title":"Evidence for a relationship between Leishmania load and clinical manifestations","volume":"87","author":"Manna","year":"2009","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.jvacx.2019.100048_b0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tvjl.2008.05.018","article-title":"The development of a real-time PCR assay for the quantification of Leishmania infantum DNA in canine blood","volume":"182","author":"de Paiva Cavalcanti","year":"2009","journal-title":"Vet J"},{"key":"10.1016\/j.jvacx.2019.100048_b0070","first-page":"330","article-title":"Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum","volume":"13","author":"Cavaliero","year":"1999","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvacx.2019.100048_b0075","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pt.2017.05.005","article-title":"Novel areas for prevention and control of canine leishmaniosis","volume":"33","author":"Miro","year":"2017","journal-title":"Trends in Parasitology"},{"key":"10.1016\/j.jvacx.2019.100048_b0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00034983.1994.11812879","article-title":"Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy","volume":"88","author":"Alvar","year":"1994","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.jvacx.2019.100048_b0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.rvsc.2005.09.011","article-title":"Parasite density and impaired biochemical\/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis","volume":"81","author":"Reis","year":"2006","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.jvacx.2019.100048_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12493","article-title":"Dog skin parasite load, TLR-2, IL-10 and TNF-alpha expression and infectiousness","volume":"39","author":"Pereira-Fonseca","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.jvacx.2019.100048_b0095","doi-asserted-by":"crossref","first-page":"e2583","DOI":"10.1371\/journal.pntd.0002583","article-title":"Heterogeneities in Leishmania infantum infection: using skin parasite burdens to identify highly infectious dogs","volume":"8","author":"Courtenay","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2019.100048_b0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vetpar.2018.03.010","article-title":"Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum","volume":"254","author":"Viana","year":"2018","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.jvacx.2019.100048_b0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2017.00217","article-title":"A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden","volume":"8","author":"Roatt","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2019.100048_b0110","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1016\/j.vaccine.2018.08.087","article-title":"Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis","volume":"36","author":"Toepp","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0115","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0125","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0130","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.4049\/jimmunol.1301810","article-title":"Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function","volume":"191","author":"Esch","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jvacx.2019.100048_b0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pt.2012.07.001","article-title":"T cell exhaustion in protozoan disease","volume":"28","author":"Gigley","year":"2012","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.jvacx.2019.100048_b0140","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2016.09.016","article-title":"Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant","volume":"34","author":"Schaut","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100048_b0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-3155-12-17","article-title":"A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7","volume":"12","author":"Fox","year":"2014","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.jvacx.2019.100048_b0150","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4049\/jimmunol.1000238","article-title":"Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis","volume":"185","author":"Raman","year":"2010","journal-title":"J Immunol"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013621930049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013621930049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:03:22Z","timestamp":1762913002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259013621930049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"alternative-id":["S259013621930049X"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100048","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in L. infantum-infected dogs","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100048"}}